Saturday, October 17, 2026 · Edition updated 6:00 AM ETSAT, OCT 17 · 6 AM ET editionNext edition in Next --:--:--

Can an amino acid supplement help older adults with depression and memory decline?

Recruiting · IRCCS Centro San Giovanni di Dio Fatebenefratelli

What this means

This trial will give 84 older adults with depression either L-serine or a placebo for 48 weeks. Researchers will check thinking skills, mood, brain activity, and body samples, but the results are not in yet.

Plain-English summary written by an AI model from the registry listing.

Status
Recruiting
Who can join
Ages 65–85 · 84 older adults with late-life depression (trial recruiting, no results posted)
Where
1 site

Contacts and how to join ↗

The science

Registered title
Effects of Specific Amino Acid Supplementation and Lifestyle Factors on Brain Ageing
Phase
Not applicable
Study type
interventional
Conditions
Late-Life Depression
What is tested
L-serine supplementation, Placebo
Sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Ages
65 Years to 85 Years
Dates
First posted Mar 27, 2026 · updated Mar 27, 2026

Registry summary

The aim of this clinical trial is to investigate the effects of L-serine supplementation on cognitive decline and psychosocial functioning in older adults with late-life depression (LLD). The study will evaluate changes in depressive symptoms, neural and cognitive functioning, and will assess neurophysiological, metagenomic, and biochemical alterations associated with L-serine supplementation compared with placebo.

The main research questions are:

  • Does L-serine supplementation affect cognitive function, depressive symptoms, and neural functioning in individuals with late-life depression?
  • What biological mechanisms may underlie the effects of L-serine on cognitive decline? Participants will be randomly assigned to one of two study arms: an intervention group (total n = 42) receiving L-serine at a dose of 6 g/day for 48 weeks, and a placebo group (total n = 42) receiving 6 g/day of maltodextrin for the same duration.

All participants will be assessed at three time points: T0 (baseline, prior to trial initiation), T18 (after 18 weeks), and T48 (after 48 weeks, at the end of the trial).

At each assessment, participants will:

  • complete clinical questionnaires and a neuropsychological assessment;
  • provide blood, fecal, and urine samples;
  • undergo electroencephalographic (EEG) recordings.

Sites (1)

  • IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
Report a problem